GIP / GLP-1 / glucagon agonist
Retatrutide
An investigational triple-receptor agonist. Trial activity does not equal regulatory approval.
Why it is discussed
Next-generation metabolic and obesity research
Retatrutide is discussed because it combines GIP, GLP-1, and glucagon receptor activity and is being studied for obesity and metabolic outcomes. Promising trial results do not make online products approved, establish self-directed dosing, or confirm that a vial contains the clinical-trial molecule.
What it is
A single peptide designed for three hormone receptors.
Retatrutide, also called LY3437943, is a modified peptide that activates GIP, GLP-1, and glucagon receptors. The term triple agonist describes these three targets. It does not mean three medicines are mixed together, or that each receptor contributes equally to the overall effect.
How it works
Combining food-intake signals with a distinct glucagon pathway.
GIP and GLP-1 pathways participate in glucose-dependent insulin secretion and the regulation of food intake. Glucagon signaling adds another metabolic pathway: it can promote glucose release from the liver and influence energy expenditure. The combined effect cannot be understood by assuming all three signals simply lower glucose.
In the original mouse experiments, reduced food intake and glucagon-receptor-related increases in energy expenditure contributed to weight changes. That animal result does not establish the size of each contribution in humans. Human trials examine the net clinical effects of the studied preparation separately.
Understanding the receptor targets does not establish long-term safety, justify self-directed use, or verify the contents of a product sold under the retatrutide name.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Ongoing and published investigational human trials
Formal human trials provide emerging evidence about the investigational molecule in controlled study settings.
There is no general marketing authorization, and trial results do not establish the identity or suitability of products sold outside the studies.
Regulatory status
Canada and the United States are checked separately.
No Health Canada-authorized product identified in the current source review.
Not FDA approved; FDA states it cannot be used in compounding under federal law.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.